About 21st North (OTCMKTS:ULGX)
21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:ULGX
- CUSIP: N/A
- Web: www.urologix.com
- 52 Week Range: $0.00 - $0.00
Sales & Book Value:
- Trailing P/E Ratio:
- Foreward P/E Ratio: -0.01
- P/E Growth:
- Annual Revenue: $12 million
- Price / Sales: 0.00
- Book Value: ($0.38) per share
- Price / Book: -0.01
- Average Volume: 36,586 shs.
- Beta: 4.29
- Short Ratio: 1.02
Frequently Asked Questions for 21st North (OTCMKTS:ULGX)
What is 21st North's stock symbol?
21st North trades on the OTCMKTS under the ticker symbol "ULGX."
How were 21st North's earnings last quarter?
21st North Inc (OTCMKTS:ULGX) posted its earnings results on Thursday, February, 5th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.80 million. View 21st North's Earnings History.
Who are some of 21st North's key competitors?
Some companies that are related to 21st North include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), Merck & Co. (MRK), UnitedHealth Group (UNH), Sanofi SA (SNY), Medtronic plc. (MDT), Bayer AG (BAYRY), Amgen (AMGN), GlaxoSmithKline plc (GSK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Celgene (CELG), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Gilead Sciences (GILD) and Eli Lilly and Co (LLY).
How do I buy 21st North stock?
Shares of 21st North can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of 21st North stock cost?
One share of 21st North stock can currently be purchased for approximately $0.00.
Consensus Ratings for 21st North (OTCMKTS:ULGX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for 21st North (OTCMKTS:ULGX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for 21st North (OTCMKTS:ULGX)Earnings History by Quarter for 21st North (OTCMKTS:ULGX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/5/2015||Q215||($0.02)||$3.80 million||$3.10 million||View||Listen|
|8/19/2014||Q4 14||($0.17)||$3.29 million||View||N/A|
|11/14/2012||Q113||($0.06)||($0.05)||$4.48 million||$4.00 million||View||N/A|
Earnings Estimates for 21st North (OTCMKTS:ULGX)
Current Year EPS Consensus Estimate: $-0.210 EPS
Next Year EPS Consensus Estimate: $-0.230 EPS
Dividend History for 21st North (OTCMKTS:ULGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for 21st North (OTCMKTS:ULGX)
Insider Ownership Percentage: 8.50%Insider Trades by Quarter for 21st North (OTCMKTS:ULGX)
Institutional Ownership Percentage: 0.09%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/26/2013||Gregory Fluet||CEO||Buy||17,500||$0.31||$5,425.00|| |
|7/12/2013||Mitchell Dann||Director||Buy||20,000||$0.30||$6,000.00|| |
|7/10/2013||Gregory Fluet||CEO||Buy||25,000||$0.24||$6,000.00|| |
|7/9/2013||Lisa A Ackermann||EVP||Buy||18,500||$0.24||$4,440.00|| |
|7/8/2013||Gregory Fluet||CEO||Buy||66,400||$0.19||$12,616.00|| |
Headline Trends for 21st North (OTCMKTS:ULGX)
Latest Headlines for 21st North (OTCMKTS:ULGX)
21st North (ULGX) Chart for Tuesday, May, 23, 2017